Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular assemblies of the catalytic domain of SOS with KRas and oncogenic mutants
Zahra Moghadamchargari, Mehdi Shirzadeh, Chang Liu, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 12
Open Access | Times Cited: 22

Showing 22 citing articles:

Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Chunxiao Zhu, Xiaoqing Guan, Xinuo Zhang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 132
Classification ofKRAS-Activating Mutations and the Implications for Therapeutic Intervention
Christian W. Johnson, Deborah L. Burkhart, Kevin M. Haigis
Cancer Discovery (2022) Vol. 12, Iss. 4, pp. 913-923
Open Access | Times Cited: 63
Discovery of Potential KRAS‐SOS1 Inhibitors from South African Natural Compounds: An In silico Approach
Abdul Rashid Issahaku, Elliasu Y. Salifu, Clement Agoni, et al.
ChemistrySelect (2023) Vol. 8, Iss. 24
Closed Access | Times Cited: 35
Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant Cancers
Zehui Zhou, Guizhen Zhou, Chuan Zhou, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 6, pp. 4197-4214
Closed Access | Times Cited: 24
Reduced dynamic complexity allows structure elucidation of an excited state of KRASG13D
Fa-An Chao, Albert H. Chan, Srisathiyanarayanan Dharmaiah, et al.
Communications Biology (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 14
From bench to bedside: current development and emerging trend of KRAS-targeted therapy
Yi Chen, Qiu-pei Liu, Hua Xie, et al.
Acta Pharmacologica Sinica (2023) Vol. 45, Iss. 4, pp. 686-703
Closed Access | Times Cited: 13
Targeting RAS mutants in malignancies: successes, failures, and reasons for hope
Hang Yang, Xinyi Zhou, Dongliang Fu, et al.
Cancer Communications (2022) Vol. 43, Iss. 1, pp. 42-74
Open Access | Times Cited: 20
Native mass spectrometry-directed drug discovery: Recent advances in investigating protein function and modulation
Francesco Fiorentino, Dante Rotili, Antonello Mai
Drug Discovery Today (2023) Vol. 28, Iss. 5, pp. 103548-103548
Open Access | Times Cited: 12
Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance
Zhiyan Jiang, Yan Li, Xin Zhou, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 100, pp. 117627-117627
Closed Access | Times Cited: 4
Monophthalates of betulinic acid and related pentacyclic triterpenes inhibit efficiently the SOS-mediated nucleotide exchange and impact PI3K/AKT signaling in oncogenic K-RAS4B proteins
Gerrit E. Benary, Frank Kilgenstein, Sascha Koller, et al.
RSC Advances (2025) Vol. 15, Iss. 2, pp. 883-895
Open Access
Adapting a Trapped Ion Mobility Spectrometry-Q-TOF for High m/z Native Mass Spectrometry and Surface-Induced Dissociation
Yu-Fu Lin, Benjamin J. Jones, Mark E. Ridgeway, et al.
Analytical Chemistry (2025)
Closed Access
In Silico Identification of Putative Allosteric Pockets and Inhibitors for the KRASG13D-SOS1 Complex in Cancer Therapy
Zehra Sarica, Özge Kürkçüoğlu, Fethiye Aylin Sungur
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 3293-3293
Open Access
Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants
Imran Khan, Akiko Koide, Mariyam Zuberi, et al.
Cell Reports (2022) Vol. 38, Iss. 6, pp. 110322-110322
Open Access | Times Cited: 17
Direct GDP-KRASG12C inhibitors and mechanisms of resistance: the tip of the iceberg
Joshua C. Rosen, Adrian G. Sacher, Ming‐Sound Tsao
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 10
2′-Deoxy Guanosine Nucleotides Alter the Biochemical Properties of Ras
Sangho D. Yun, Elena Scott, Zahra Moghadamchargari, et al.
Biochemistry (2023) Vol. 62, Iss. 16, pp. 2450-2460
Open Access | Times Cited: 7
Nucleotide Exchange on RAS Proteins Using Hydrolysable and Non-hydrolysable Nucleotides
Timothy J. Waybright, Andrew Stephen
Methods in molecular biology (2024), pp. 35-46
Closed Access | Times Cited: 2
Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma
Larissa Haertle, Umair Munawar, Hipólito Nicolás Cuesta Hernández, et al.
HemaSphere (2024) Vol. 8, Iss. 7
Open Access | Times Cited: 2
Capturing RAS oligomerization on a membrane
Sangho D. Yun, Elena Scott, Jing‐Yuan Chang, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 34
Open Access | Times Cited: 2
Autopromotion of K-Ras4B Feedback Activation Through an SOS-Mediated Long-Range Allosteric Effect
Xuan He, Kui Du, Yuanhao Wang, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 11
CSC01 shows promise as a potential inhibitor of the oncogenic G13D mutant of KRAS: an in silico approach
Olanrewaju Ayodeji Durojaye, Umer Ejaz, Henrietta Onyinye Uzoeto, et al.
Amino Acids (2023) Vol. 55, Iss. 12, pp. 1745-1764
Closed Access | Times Cited: 6
Studying early structural changes in SOS1 mediated KRAS activation mechanism
Kirti Bhadhadhara, Vinod Jani, Shruti Koulgi, et al.
Current Research in Structural Biology (2023) Vol. 7, pp. 100115-100115
Open Access | Times Cited: 4
Biophysical Characterization of RAS-SOS Complexes by Native Mass Spectrometry
Sangho Yun, Elena Scott, Arthur Laganowsky
Methods in molecular biology (2024), pp. 177-193
Closed Access
Page 1

Scroll to top